Ann: Rett Syndrome Patients to Receive NTI164 for 52 Weeks, page-14

I tend to agree, a lot of reputation on the line for the three professors, Id believe they wouldn't tout something unless they had both scientific and trial evidence to back up their claims.

I think investors here may be overlooking that most trial patients are very ill, After treatment, moving from Severely ill to moderately and even mildly ill, can have a huge positive impact on their lives and also those around them. The positive behavioural impacts on those suffering and the positive effect it has on those around them, means a better and improved life for all. These illnesses currently lack an effective treatment that doesn't come packed full of what id consider nasty side effects.

Exciting few weeks, all we need is efficacy across the trials, I personally am not concerned about the safety profile as I think having all kids continuing their treatments and the data which already is in the public space, gives me full confidence that NTI164 is very tolerable